Trial
NCT03570476
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI); AstraZeneca
Condition
Prostate Adenocarcinoma Without Neuroendocrine Differentiation
Intervention
Olaparib
Why stopped
Terminated due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-21